CoChat

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

Marcus, Leigh, Lemery, Steven J., Keegan, Patricia, Pazdur, Richard · 2019 · Clinical Cancer Research

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

The FDA approved pembrolizumab on May 23, 2017, for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H), or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options and for the treatment of unresectable or metastatic MSI-H or dMMR colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. The FDA granted the approval based on an understanding of the biology of MSI-H/dMMR across different tumors along with the clinically important effects on overall response rate (ORR) observed in patients who were enrolled in 1 of 5 single-arm clinical trials. The ORR was 39.6% among 149 patients with 15 different tumor types (95% confidence interval, 31.7–47.9), with a 7% complete response rate. The duration of response ranged from 1.6+ months to 22.7+ months, with 78% of responses lasting ≥6 months. Overall, the adverse event profile of pembrolizumab was similar to the adverse event profile observed across prior trials that supported the approval of pembrolizumab in other indications. This approval of pembrolizumab is the first time that the FDA has approved a cancer treatment for an indication based on a common biomarker rather than the primary site of origin.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-4070

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 18 references

Research works printed but not linked: 3

  1. Full prescribing information: KEYTRUDA
  2. U.S. Food and Drug Administration, BLA 125514/S-14 approval letter
  3. U.S. Food and Drug Administration, 2014, In vitro companion diagnostic devices guidance for industry and Food and Drug Administration staff

Cited by

See all 1,176

Metadata

Authors
Marcus, L., Lemery, S. J., Keegan, P., & Pazdur, R.
Affiliations
United States Food and Drug Administration (US)
Corresponding author
Marcus, Leigh
Venue
Clinical Cancer Research
Published
2019-07-01
Volume
25
Issue
13
Pages
3753-3758
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2915944698
Cited by
1,176
References
18
Citations by year
2026: 106 · 2025: 129 · 2024: 145 · 2023: 192 · 2022: 188 · 2021: 220 · 2020: 153 · 2019: 41
FWCI
62.91
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
HHS | U.S. Food and Drug AdministrationHHS | U.S. Food and Drug Administration (FDA) (n/a)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
pembrolizumab, microsatellite instability-high, mismatch repair deficiency, solid tumors, colorectal cancer, immune checkpoint inhibitors, FDA drug approval, overall response rate, adverse events, metastatic cancer
MeSH terms
Antineoplastic Agents, Immunological, Clinical Trials as Topic, Drug and Narcotic Control, Humans, Neoplasms, Prognosis, United States, United States Food and Drug Administration, Treatment Outcome, Drug Approval, Kaplan-Meier Estimate, Microsatellite Instability, DNA Mismatch Repair, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-4070
The paper
Marcus, L., Lemery, S. J., Keegan, P., & Pazdur, R. (2019). FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-4070

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.